



**UNITED STATES DEPARTMENT OF COMMERCE**

**United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/616,962 07/14/00 CARTER

D P06652US0/BA

000881  
LARSON & TAYLOR, PLC  
1199 NORTH FAIRFAX STREET  
SUITE 900  
ALEXANDRIA VA 22314

HM12/1002

EXAMINER

SISSON, B

ART UNIT

PAPER NUMBER

1655

DATE MAILED:

10/02/01

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

**Office Action Summary**

Application No.

09/616,962

Applicant(s)

CARTER, DANIEL C.

Examiner

Bradley L Sisson

Art Unit

1655

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) 16-20 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-15 and 21 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 14 July 2000 is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s) \_\_\_\_.
- 2) ☒ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_ 6) ☒ Other: *See Continuation Sheet*.

Continuation of Attachment(s) 6). Other: Notice to Comply with Sequence Rules.

**DETAILED ACTION**

***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-6, 8-15, and 21, drawn to isolated human serum albumin, classified in class 530, subclass 363; and claim 7, drawn to a pharmaceutical comprising said serum albumin, classified in class 514, subclass 2.
  - II. Claims 16-20, drawn to nucleic acid, classified in class 536, subclass 23.5.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the inventions are drawn to different chemical compounds that have different effects.
3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
4. During a telephone conversation with B., Aaron Schulman on 25 September 2001 a provisional election was made without traverse to prosecute the invention of Group I, claims 1-15 and 21. Affirmation of this election must be made by applicant in replying to this Office action. Claims 16-20 have been withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

*Specification*

5. The disclosure is objected to because of the following informalities: The specification has been found to contain disclosures of amino acid sequences that are not accompanied by a SEQ ID NO., nor has a Sequence Listing been found to be a part of the subject application.

Appropriate correction is required.

*Claim Rejections - 35 USC § 112*

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1-15 and 21 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in *In re Wands*, 8 USPQ2d 1400 (CAFC 1988). They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

*The Quantity of Experimentation Necessary*

The quantity of experimentation need is great, on the order of several man-years and then with little, if any, reasonable expectation of success.

*The Amount of Direction or Guidance Provided*

The specification has been found to provide very limited guidance.

*The Presence or Absence of Working Examples*

The specification sets forth but two examples. Neither examples addresses the aspect of making a single amino acid modification (claims 1-7) and none of the examples teach the production of any protein, much less the production of the modified human serum albumin via recombinant means such as in any plant (claims 11 and 12). The two examples, pages 15-16 of the specification, teach modifying human serum albumin by adding 7 amino acids to the n-terminus. Specifically, the amino acids Glu-Ala-Glu-Phe-Asp-Ala-His were added. The protein was not produced via recombinant means but through chemical means.

*The Nature of the Invention*

The claimed invention relates directly to matters of physiology and chemistry, which are inherently unpredictable and as such, require greater levels of enablement. As noted in *In re*

*Fisher* 166 USPQ 18 (CCPA, 1970):

In cases involving predictable factors, such as that, once imagined, other embodiments can be made without difficulty and their performance characteristics predicted by resort to known scientific laws. In cases involving unpredictable factors, such as most chemical reactions and physiological activity, the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved.

*The State of the Prior Art*

The state of the prior art is one that has shown increased interest in the production of human serum albumin. The art had advanced to the point where a single amino acid, Histidine, in site VI was recognized as being responsible to the binding of copper and nickel.

*The Relative Skill of Those in the Art*

The relative skill of those in the art that is most closely associated with the claimed invention is high, on par with those that hold a Ph.D. in biochemistry.

*The Breadth of Scope of the Claims*

The claims have been interpreted as encompassing any and all variants of human serum albumin that can have any number of modifications to the amino acid sequence. While claim 2 limits claim 1 to where the mutation "is a single amino acid," claim 1 allows for any number of modifications. Support for such an interpretation is found in the language "at least a one-amino acid truncation" and where in claim 3 "the mutation comprises an elongation or insertion."

8. Claims 1-15 and 21 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. As presently worded, the claims have been interpreted as encompassing many thousands of different species of human serum albumin yet the disclosure has been found to set forth an adequate written description of but one species within this genus. It is well settled that the disclosure of a single species is rarely sufficient to adequately describe

Art Unit: 1655

the genus. In support of this position, attention is directed to the decision in *In re Shokal*, 113

USPQ 283 (CCPA 1957) wherein is stated:

It appears to be well settled that a single species can rarely, if ever, afford sufficient support for a generic claim. *In re Soll*, 25 C.C.P.A. (Patents) 1309, 97 F.2d 623, 38 USPQ 189; *In re Wahlforss et al.*, 28 C.C.P.A. (Patents) 867, 117 F.2d 270, 48 USPQ 397. The decisions do not however fix any definite number of species which will establish completion of a generic invention and it seems evident therefrom that such number will vary, depending on the circumstances of particular cases. Thus, in the case of small genus such as the halogens, consisting of four species, a reduction to practice of three, or perhaps even two, might serve to complete the generic invention, while in the case of a genus comprising hundreds of species, a considerably larger number of reductions to practice would probably be necessary.

\*\*\*

We are of the opinion that a genus containing such a large number of species cannot properly be identified by the mere recitation or reduction to practice of four or five of them. As was pointed out by the examiner, four species might be held to support a genus, if such genus is disclosed in clear language; but where those species must be relied on not only to illustrate the genus but to define what it is, the situation is otherwise.

### *Claim Rejections - 35 USC § 103*

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

10. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.



Art Unit: 1655

2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

11. Claims 1-15 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Carter in view of Carter et al.

Carter (US Patent 5,780,594) discloses at length the production of human serum albumin that may comprise virtually any modification and that it may of virtually any length. Support for this interpretation is based in part on where at column 3 where it is disclosed that the human serum albumin is to comprise "at least one <sup>of</sup> the binding sites." Such breadth of scope is B76 considered to encompass not only a single binding site, but additional binding sites, up to and including all binding sites. Carter also discloses at column 5 and 6 that the serum albumin may have modified or similar binding properties as encountered with natural serum albumin.

Carter, column 5 and 6, discloses the production of a serum albumin via recombinant means. At column 6, last paragraph, the aspect of changing one or more amino acids so to arrive at a serum albumin with the requisite binding properties is also disclosed.

Carter provides motivation for making modified human serum albumin where at column 1 it is stated that "[c]urrently, there are literally thousands of applications for serum albumin protein and its related proteins...."

Carter et al., page 189, disclose that removal of the His residue in site VI (N-terminus of human serum albumin) will greatly reduce the capacity of human serum albumin to bind trace metals such as copper and nickel.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the modifications to the amino acid sequence of human serum albumin,

Art Unit: 1655

be it the addition of one or more amino acids or the deletion of same from the structure of human serum albumin so to produce a serum albumin that has the requisite binding properties as the structure of human serum albumin was well known and the specific binding sites had been identified and the art taught explicitly of modifying the structure so to produce the desired protein. In view of the motivation provided in the art and the reproducible nature of the art, the ordinary artisan would have been both highly motivated and would have had a reasonable expectation of success.


### *Conclusion*

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L Sisson whose telephone number is (703) 308-3978. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3592 for regular communications and (703) 308-0294 for After Final communications.

Art Unit: 1655

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



Bradley L. Sisson  
Primary Examiner  
Art Unit 1655

bls  
September 30, 2001